CureVac
177 articles about CureVac
-
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
1/5/2024
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced positive interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19.
-
A court in Germany on Tuesday nullified one of CureVac’s intellectual property rights in a patent case against BioNTech. However, court proceedings involving seven other patent rights will continue.
-
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
11/14/2023
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update.
-
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
11/1/2023
CureVac N.V. today announced solid progress in its clinical vaccine development programs in COVID-19 and seasonal flu, conducted in collaboration with GSK.
-
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
9/12/2023
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced selection of a promising vaccine candidate for continued clinical development based on positive data from an interim analysis of the ongoing Phase 1 part of a combined Phase 1/2 study, conducted in collaboration with GSK.
-
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
8/17/2023
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the second quarter and first half of 2023 and provided a business update.
-
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
8/1/2023
CureVac N.V. today announced that the first participant was dosed in the Phase 2 study of monovalent and bivalent modified mRNA COVID-19 vaccine candidates, developed in collaboration with GSK.
-
CureVac Announces Update to the Management Team
7/14/2023
CureVac N.V. today announced that Dr. Igor Splawski, CureVac's Chief Scientific Officer, will step down effective July 14, 2023 to return to early-stage research in the United States.
-
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
7/13/2023
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that it has strengthened its position in the ongoing patent litigations with Pfizer/BioNTech in Germany and the U.S. by expanding the scope of both cases by asserting new intellectual property rights.
-
CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma
6/20/2023
CureVac N.V. today announced that it has dosed the first patient with its investigational cancer vaccine CVGBM in a Phase 1 study.
-
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
6/20/2023
CureVac N.V. today announced the appointment of Michael Brosnan as an independent director to the company's Supervisory Board.
-
CureVac Announces Voting Results of General Meeting - June 19, 2023
6/19/2023
CureVac N.V. announced the voting results of the Company's annual general meeting.
-
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
5/30/2023
CureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the first quarter of 2023 and provided a business update.
-
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
5/19/2023
Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline.
-
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
5/8/2023
CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.
-
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
4/25/2023
CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the fourth quarter and full-year 2022 and provided a business update.
-
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
4/18/2023
CureVac N.V. will report financial results, and provide business updates for the fourth quarter and full-year 2022 on Tuesday, April 25, 2023.
-
CureVac Announces Voting Results of Extraordinary General Meeting
3/28/2023
CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company's extraordinary general meeting.
-
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
2/10/2023
CureVac N.V. announced the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by CureVac.
-
CureVac Announces Proposed Public Offering of Common Shares - February 07, 2023
2/7/2023
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that it intends to offer $200 million of its common shares in an underwritten public offering.